Modification of the anti‐CD3‐induced cytokine release syndrome by anti‐interferon‐γ or anti‐interleukin‐6 antibody treatment: Protective effects and biphasic changes in blood cytokine levels
- 1 September 1993
- journal article
- research article
- Published by Wiley in European Journal of Immunology
- Vol. 23 (9) , 2209-2216
Abstract
Anti‐interferon‐γ (IFN‐γ) antibodies were found to protect mice against pathological changes induced by injection of anti‐CD3 antibody: incidence of diarrhea, severity of hypothermia and mortality rates were dramatically reduced. In anti‐IFN‐γ antibody‐treated mice, IFN‐γ blood levels were significantly reduced at 1.5 h post anti‐CD3 challenge, but more elevated levels were found from 4 to 24 h. This rebound‐like IFN‐γ response coincided with more profound hypoglycemia. Tumor necrosis factor and interleukin (IL)‐6 levels were not affected by anti‐IFN‐γ treatment. Exogenous IFN‐γ, administered within 3 h (but not later) of the anti‐CD3 challenge made the syndrome worse. Furthermore, inter‐mouse strain differences in sensitivity to the anti‐CD3 syndrome correlated with the ability of the strain to produce IFN‐γ. Anti‐IL‐6 antibodies provided only marginal protection against hypothermia and mortality, but did markedly reduce hypoglycemia. Levels of biologically active IL‐6 in serum were not influenced by anti‐IL‐6 antibody treatment during the first few hours after anti‐CD3 challenge, but were significantly increased at later times.The data provide evidence that endogenous IFN‐γ is a critical element in the early phase of the anti‐CD3 syndrome; endogenous IL‐6, while possibly being involved in hypoglycemia, seems of lesser importance for the outcome of the syndrome.Keywords
This publication has 31 references indexed in Scilit:
- EVIDENCE THAT ANTIHUMAN TUMOR NECROSIS FACTOR MONOCLONAL ANTIBODY PREVENTS OKT3-INDUCED ACUTE SYNDROMETransplantation, 1992
- Protective effect of anti‐interleukin (IL)‐6 antibody against endotoxin, associated with paradoxically increased IL‐6 levelsEuropean Journal of Immunology, 1992
- T cell-mediated lethal shock triggered in mice by the superantigen staphylococcal enterotoxin B: critical role of tumor necrosis factor.Journal of Experimental Medicine, 1992
- Interferon‐γ/lipolysaccharide‐treated mouse embryonic fibroblasts are killed by a glycolysis/l‐arginine‐dependent process accompanied by depression of mitochondrial respirationEuropean Journal of Biochemistry, 1991
- Anti-interferon-γ antibody treatment, growth of Lewis lung tumours in mice and tumour-associated cachexiaEuropean Journal of Cancer and Clinical Oncology, 1991
- REDUCTION OF MORBIDITY AND CYTOKINE RELEASE IN ANTI-CD3 MoAb-TREATED MICE BY CORTICOSTEROIDSTransplantation, 1990
- Cytokine‐related syndrome following injection of anti‐CD3 monoclonal antibody: Further evidence for transient in vivo T cell activationEuropean Journal of Immunology, 1990
- Hypothermia and hypoglycemia induced by anti‐CD3 monoclonal antibody in mice: Role of tumor necrosis factorEuropean Journal of Immunology, 1990
- The Biology of Cachectin/TNF -- A Primary Mediator of the Host ResponseAnnual Review of Immunology, 1989
- A Randomized Clinical Trial of OKT3 Monoclonal Antibody for Acute Rejection of Cadaveric Renal TransplantsNew England Journal of Medicine, 1985